Atle Fund Management AB Raises Stock Position in Bicara Therapeutics Inc. $BCAX

Atle Fund Management AB lifted its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 38.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 203,755 shares of the company’s stock after buying an additional 56,375 shares during the quarter. Bicara Therapeutics accounts for 1.3% of Atle Fund Management AB’s portfolio, making the stock its 28th biggest position. Atle Fund Management AB’s holdings in Bicara Therapeutics were worth $3,217,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vestal Point Capital LP raised its stake in Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after buying an additional 2,231,025 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the period. Bank of America Corp DE grew its holdings in shares of Bicara Therapeutics by 2,351.0% during the 2nd quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after acquiring an additional 432,818 shares during the period. Schroder Investment Management Group raised its position in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock worth $3,951,000 after acquiring an additional 383,681 shares in the last quarter. Finally, Artisan Partners Limited Partnership purchased a new position in shares of Bicara Therapeutics in the 2nd quarter valued at approximately $3,742,000.

Insider Activity

In related news, CEO Claire Mazumdar sold 41,163 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.86, for a total value of $776,334.18. Following the completion of the transaction, the chief executive officer directly owned 309,892 shares in the company, valued at $5,844,563.12. The trade was a 11.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Ryan Cohlhepp sold 3,828 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total value of $69,286.80. Following the completion of the transaction, the chief operating officer directly owned 210,164 shares in the company, valued at $3,803,968.40. This trade represents a 1.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 95,922 shares of company stock worth $1,784,142 over the last three months. 15.50% of the stock is currently owned by insiders.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $16.80 on Friday. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $19.71. The firm’s 50-day moving average is $17.52 and its 200 day moving average is $14.92. The stock has a market cap of $920.30 million, a price-to-earnings ratio of -7.50 and a beta of -0.79.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BCAX shares. Mizuho raised Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citigroup began coverage on shares of Bicara Therapeutics in a research report on Thursday. They set an “outperform” rating for the company. Citizens Jmp began coverage on shares of Bicara Therapeutics in a report on Thursday. They issued a “market perform” rating and a $31.00 price objective on the stock. Finally, Wells Fargo & Company raised their target price on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $28.33.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.